There has been a steep increase in the number of meta-analyses of genome-wide association (GWA) studies aimed at identifying genetic variants with increasingly smaller effects, but pressure to publish findings of new genetic associations has limited the time available for careful consideration of all of their methodological aspects. The authors surveyed the literature (2007)(2008)(2009)(2010) to provide empirical evidence on the methods used in GWA metaanalyses, including their organization, requirements about the uniformity of methods used in primary studies, methods for data pooling, investigation of between-study heterogeneity, and quality of reporting. This review showed that a great variety of methods are being used, but the rationale for their choice is often unclear. It also highlights how important methodological aspects have received insufficient attention, potentially leading to missed opportunities for improving gene discovery and characterization. Evaluation of power to replicate findings was inadequate, and the number of variants selected for replication was not associated with replication sample size. A low proportion of GWA meta-analyses investigated the presence and magnitude of heterogeneity, even when there was little uniformity in methods used in primary studies. More methodological work is required before clear guidance can be offered as to optimal methods or tradeoffs between alternative methods. However, there is a clear need for guidelines for reporting the results of GWA meta-analyses. epidemiologic methods; genome-wide association study; meta-analysis; review; statistics Abbreviations: GWA, genome-wide association; HWE, Hardy-Weinberg equilibrium; IQR, interquartile range; SNP, single nucleotide polymorphism.
The advent of genome-wide association (GWA) investigations, in which hundreds of thousands of single nucleotide polymorphisms (SNPs) are genotyped to capture indirectly most of the genome's common variation, has revolutionized the search for genetic risk factors for common complex diseases and has facilitated the discovery of many robustly replicated genetic associations. With few exceptions, the genetic effects characterizing these associations translate into modest increases in disease risk, with odds ratios typically below 1.5, which require large sample sizes in order to be detected (1) . The fast-growing number of GWA investigations and the need to combine findings across studies to increase statistical power have led to a steep rise in the number of GWA meta-analyses, often based on large international consortia. Recently a few groups of investigators have started to examine methodological issues in GWA meta-analyses, focusing on theoretical (2-5) and practical (6) considerations. In particular, the assessment of between-study heterogeneity has received attention (7) (8) (9) . However, as yet this work has been of interest mainly to methodologists, and it is unclear what impact it has had on practice.
Most GWA meta-analyses focus on gene discovery, that is, the identification of novel candidate genes for specific traits, rather than on gene characterization, that is, the determination of the magnitude of genetic effects and the understanding of how they vary in the presence of modifying genetic or environmental factors. This is different from the use of meta-analysis in other contexts, including candidate gene association studies, where the emphasis has more often been on estimating the magnitude of the effect, identifying heterogeneity across studies, and investigating its possible causes. Although the general impression is that methods used to meta-analyze hundreds of thousands to millions of variants from GWA studies have remained more or less the same as those first developed for clinical trials with very few outcomes (10) , to date there has not been an empirical study of actual practice in GWA meta-analysis.
In this paper, we describe methods used in published GWA meta-analyses and discuss the underlying assumptions and implications associated with the use of different methods, with the aims of helping investigators choose appropriate methods for the conduct and reporting of their GWA metaanalyses and assisting readers to correctly interpret GWA meta-analysis findings. The review also aims at highlighting areas where further methodological investigations are required.
MATERIALS AND METHODS

Identification of papers
We identified articles on GWA meta-analyses published through the end of June 2010 using MEDLINE (National Library of Medicine). The search strategy was organized in 2 blocks using the following keywords and Medical Subject Headings: [(meta-analy* or metaanaly* or metanaly* or pooled analy* or consorti*) or meta-analysis/] and [(genome wide or genomewide or GWA or whole genome) or genomewide association study/].
Selection of GWA meta-analysis papers on either binary or continuous traits was performed in duplicate. We excluded meta-analyses performed on a subset of SNPs, such as ''top hits'' (SNPs with the lowest P values) of a GWA study published previously or reported within the same paper. We also excluded meta-analyses of genome-wide linkage studies.
Data extraction
Duplicate data extraction was performed using a prepiloted form with multiple-choice responses to maximize consistency between reviewers (see Web Table 1 , which is posted on the Journal's website (http://aje.oxfordjournals. org/)). Data extracted covered information on: 1) studies included in the meta-analysis (primary studies), with emphasis given to the uniformity of methods used (study design, genotyping platform, genotyping quality control, imputation method, detection and correction for cryptic relatedness and population stratification); 2) GWA meta-analysis, including number of studies and total sample size, use of online data, pooling method, genetic model, assessment of heterogeneity, secondary analyses (subgroup and sensitivity analyses, conditional analyses, haplotype analyses), exploration of other issues (variance explained, risk score, gene-gene and gene-environment interactions), and functional follow-up of findings; and 3) replication of GWA meta-analysis findings, including number of replication studies and total sample size, use of online data, criteria for selection of SNPs for replication, form of replication (in silico, de novo genotyping), criteria for declaring replication (based on replication sample only or combined discovery and replication samples), statistical significance threshold used, and assessment of power to replicate. To avoid assigning excessive weight to papers reporting on more meta-analyses, we selected only 1 continuous outcome and/or 1 binary outcome per paper (main outcome or first outcome listed if the authors did not distinguish between primary and secondary outcomes).
Data analysis
Data were analyzed for the whole sample and separately by type of outcome (continuous vs. binary), with further subgroup analyses being performed by year of publication and impact factor of the journal.
As a way to summarize all of the evidence collected and in order to identify patterns of response within our questionnaire, we performed a principal component analysis of 43 questions (see Web Appendix). By analyzing the degree of correlation between questions, principal component analysis can identify important clusters of characteristics of the conduct and reporting of GWA meta-analyses (11) .
In order to provide some empirical evidence on the power to replicate findings given the replication sample size, among SNPs selected for replication we performed power calculations for both the SNP with the largest effect estimate and the SNP with the smallest effect estimate in the discovery meta-analysis. When not reported, standard errors for the effect estimates were calculated from 95% confidence intervals or P values if available. Power calculations were performed assuming a significance threshold of 0.05, corrected for multiple testing (Bonferroni correction), from a 1-sided test.
All analyses were performed using Stata, version 10.1 (StataCorp LP, College Station, Texas).
RESULTS
Of the 727 papers identified in MEDLINE, 81 met the inclusion criteria and were included in the review; reasons for exclusion are reported in Web Figure 1 . Four papers were published in 2007, 14 in 2008, 36 in 2009, and 27 between January and June 2010, with the most represented journals being Nature Genetics (52%), the American Journal of Human Genetics (9%), and PLoS Genetics (7%). The 81 papers reported on 86 GWA meta-analyses (Web Table 2 ), of which 48 were on continuous outcomes, 37 were on binary outcomes, and 1 was on a categorical outcome. Online supplementary material was available for nearly all papers (98%).
Methods used in primary studies
Findings on primary studies, with a focus on the uniformity of methods used across them, are reported in Web Table 3 . In general, uniformity of the methods of primary studies was higher in smaller meta-analyses ( Figure 1 ). Uniformity of study design was observed in 42% of meta-analyses overall, but it varied by type of outcome. For continuous outcomes, study design was the same across studies in only 20% of meta-analyses, reflecting a frequent mix of populationbased and family-based designs, while for binary outcomes uniformity was observed in 70%, with the case-control design being used in the majority of meta-analyses. Genotyping platforms were the same in only 16% of meta-analyses, while the rest used different platforms, mainly from different manufacturers.
For genotyping quality control, 95% of meta-analyses used a Hardy-Weinberg equilibrium (HWE) P value threshold for excluding SNPs, but only 60% of these reported thresholds for every study, among which 58% had the same threshold, most commonly 10
À6
. Similarly, 91% of meta-analyses used a minor allele frequency threshold, but among them only 50% reported all individual thresholds, and of these, 87% used the same threshold, overwhelmingly 0.01. Thresholds for SNPwise and individual-wise call rates were used in 97% and 74% of meta-analyses, respectively, with all individual thresholds reported in 64% and 53%. When reported, thresholds were the same across studies in 47% and 44%, most commonly being 0.95.
Seventy-four percent of meta-analyses were based on imputed genotypes (including allelic dosage), although the frequency of imputation was much higher for continuous outcomes than for binary outcomes. In the 13 meta-analyses (15%) where imputation was not used and different genotyping platforms had been employed (from the same manufacturer in 12 of them), meta-analysis was performed on overlapping SNPs. In less than 40% was the imputation program the same across studies, and when it was, MACH (12) was the most widely used. The HapMap release and the National Center for Biotechnology Information build were the same in 45% and 22% of meta-analyses, respectively, with such information being either reported only for some studies or not reported at all in 39% and 55%.
The GWA analysis in primary studies was adjusted for covariates in 72% of meta-analyses, with three-quarters of these using the same covariates across studies; age and sex were by far the most common covariates. In the majority of meta-analyses, identification of population stratification and cryptic relatedness based on genomic data was performed in only some of the population-based studies included. Correction for cryptic relatedness was performed by excluding first-and second-degree relatives, with one exception in which exclusion was extended to more distant relatedness (13) . Population stratification was mainly identified through principal component analysis using EIGENSTRAT software (14) , with correction being performed mostly by omitting persons identified as ethnic outliers, or less commonly by adjusting for the first principal components. Genomic inflation factors (lambda) were reported for 77% of meta-analyses, and 22% also included the quantile-quantile plots. For both, the information was usually presented for all studies. The largest study-specific lambda value within a meta-analysis ranged from 1.01 to 1.6. Such a value was smaller in the 49% of meta-analyses where no study-specific correction was applied based on lambda (P < 0.01). 
Methods used for GWA meta-analysis
Findings on methods used in GWA meta-analysis are reported in Web Table 4 . The number of studies included and the total meta-analysis sample size varied widely (Table 1) , and this was associated with year of publication (Web Table 5 ). The median number of studies per meta-analysis increased from 2. GWA study results publicly available on the World Wide Web were included in 19% of meta-analyses. GWA metaanalysis results for all SNPs analyzed were made publicly available online in 15% of meta-analyses overall, and this happened more often for binary outcomes than for continuous outcomes (27% vs. 6%; P ¼ 0.01). Most meta-analyses used summary results from GWA studies, with only 13% using individual-level data. The X chromosome was analyzed in less than one-quarter of meta-analyses, and most of those investigators did not report the method used. Among those who did, the most commonly used approach was Clayton's method of treating males as homozygous females (15) . All GWA meta-analyses assumed an additive genetic model, although 6 also considered alternative genetic models (recessive or dominant) or pairwise genotype comparisons in secondary analyses on top hits. In one meta-analysis, different models were compared using Akaike's Information Criterion (16) .
The pooling was performed on effect sizes in most metaanalyses (beta coefficients for continuous outcomes and log odds ratios or similar estimates for binary outcomes). In the 24% of meta-analyses that pooled P values, almost all used a z score method which accounts for effect direction, the one exception using Fisher's method; often this was accompanied by a secondary pooling of effect sizes to estimate the magnitude of the genetic effect. In approximately one-third of the meta-analyses of continuous outcomes, the individualstudy-level analysis was performed on residuals rather than on the original phenotype data, mainly to allow adjustment for relatedness and less frequently to adjust for covariates such as age and sex. The majority of the meta-analyses used inverse-variance weighting, less commonly sample-size weighting, and rarely Cochran-Mantel-Haenszel weighting. Fixed-effects models were always used as the primary GWA meta-analysis, with one exception using both fixed-and random-effects models (17) . In 8 other meta-analyses, the investigators applied a random-effect model as a secondary analysis on top hits, either on all of them or on those for which heterogeneity was detected. In only about 70% of the meta-analyses did investigators report the software used for pooling, with METAL (18) being the most common one.
A quantile-quantile plot, usually based on log 10 P values, and a genomic control lambda value for pooled results were reported in approximately two-thirds of meta-analyses, with lambda correction of pooled results being applied in 15%. Only 27% of meta-analyses used forest plots to represent results for the top hits. Results of heterogeneity tests were reported in 48% of meta-analyses, while a measure of the magnitude of heterogeneity, most commonly I 2 , was reported in only 27%. In all but 3 meta-analyses, investigators reported the P value threshold used to declare genome-wide statistical significance. Thresholds varied for GWA metaanalyses based on genotyped data versus imputed data. All meta-analyses on genotyped SNPs but one used a Bonferroni correction accounting for the actual number of SNPs analyzed, the exception using permutation (19) . Most metaanalyses on imputed data used a threshold of 5 3 10 À8 ; 4 meta-analyses used 5 3 10 À7 , and 2 used 10 À7 , with other thresholds being used in single meta-analyses (10 À8 in a meta-analysis of African Americans; 5 3 10 À8 /3 in a 3-stage GWA meta-analysis; 7.2 3 10 À8 ; 1.6 3 10 À7 based on Bonferroni correction; 4.4 3 10 À7 based on a false discovery rate approach; and 10
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). Haplotype analysis was much more frequent in metaanalyses on individual-level data (42% vs. 9%; P ¼ 0.01) and was performed around the identified SNPs in all but 2 papers, where it was carried out at the genome-wide level (19, 20) . Less than half of the meta-analyses estimated the proportion of the trait variance explained by the effects of the identified SNPs, either individually or in combination, although this was much more common for continuous outcomes than for binary outcomes (65% vs. 24%; P < 0.001).
Genetic risk score analysis for the identified SNPs was performed in 20% of meta-analyses. Genome-wide subgroup analyses, most commonly by sex, were reported in 16% of meta-analyses, but interactions were never formally investigated at the genome-wide level. Gene-gene interactions, and much less commonly geneenvironment interactions, were evaluated for top hits in 18% of meta-analyses, and for binary outcomes a case-only approach was often used. Gene-expression analysis for the identified SNPs was performed in 30% of meta-analyses, with publicly available gene-expression data being used much more often for binary outcomes than for continuous outcomes (46% vs. 13%; P ¼ 0.09).
Methods used for replication of GWA meta-analysis findings
Findings on methods used for replication are reported in Web Table 6 . Replication was performed in 80% of metaanalyses, with inclusion of online data in 9% of these. The size of the replication varied widely (Table 1) , with a trend for a higher number of studies and a larger total sample size for continuous outcomes versus binary outcomes. Although the finding was not statistically significant, there was a trend of an increasing number of studies and an increasing total sample size over time (Web Table 5 Figure 3A shows that the number of SNPs selected for replication did not increase with the increase in the replication sample size, in contrast to what might have been anticipated. As expected, the proportion of SNPs successfully replicated increased with the decrease in the number of SNPs considered for replication ( Figure 3B) . In approximately one-fourth of meta-analyses, the investigators performed power calculations for replication, although they were mostly post hoc calculations as opposed to a priori calculations. We could evaluate the power to replicate findings for the SNPs with the largest effect and the smallest effect for 42 meta-analyses that had information available on replication sample size, effect estimate, and standard error for all SNPs selected for replication. Findings are reported in Figure 4 , which shows that 88% of meta-analyses had power !80% to replicate their largest effect and 71% had power !80% to replicate their smallest effect. The power to replicate greatly decreased when the analyses were repeated after accounting for the ''winner's curse.'' The proportion of meta-analyses with power !80% fell to 64% and 45% for the SNPs with the largest effect and the smallest effect, when conservatively assuming a bias of 30% (i.e., the true effect is 30% smaller than the estimated effect from the discovery GWA meta-analysis). Results did not change substantially when power calculations were repeated considering the most and least significant SNPs instead of the SNPs with the largest and smallest effect estimates.
Although the specific criteria used to select SNPs for replication varied widely, they could be grouped into 2 categories: Figure 2 . Size of the replication sample according to the size of the discovery genome-wide association (GWA) meta-analysis for binary and continuous outcomes.
criteria based solely on evidence from the discovery metaanalysis (74%) and criteria that also included previous evidence in support of an association with the outcome of interest, based either on biologic knowledge or on findings from previous studies (22%). Replication involved de novo genotyping in the majority of meta-analyses, while it was purely based on genome-wide data already available (in silico) in 23%. Surrogate SNPs for variants from the discovery sample that were not available in the replication sample were used in 16% of meta-analyses, chosen on the basis of a threshold for linkage disequilibrium (r 2 ) ranging from 0.8, which was used by the majority of meta-analyses, to 0.9.
When more than 1 study was used for replication, metaanalysis was performed in 71% of cases, while in the rest replication was assessed separately in the individual studies. In 2 cases, replication samples were not pooled because of differing ethnicity (21, 22) . Replication was declared on the basis of the combined discovery and replication analysis in 51% of meta-analyses, with adjustment for multiple testing obtained using the same genome-wide significance threshold of the discovery meta-analysis, while it was based on the replication analysis alone in 38%, with adjustment for multiple testing applied in only 12% of cases using Bonferroni correction or, in one case, a false discovery rate (23) . Eighty percent of the meta-analyses declaring replication based on the replication analysis alone did not specify whether a 1-sided or 2-sided P value was used. Among those that did, 80% used 1-sided P values and 20% used 2-sided P values. Four meta-analyses used both approaches to declare replication, either as alternative criteria (n ¼ 3) or as criteria to be simultaneously satisfied (n ¼ 1).
Relation between the main methodological features
The principal component analysis of 43 questions identified 4 important clusters of characteristics of the meta-analyses (see Web Appendix and Web Figure 2 ): their uniformity in methods for conduct and reporting of primary studies, their thoroughness, their size, and the clarity of their report (Web Table 7 ). To capture these 4 features, we created scores by either counting the number of relevant questions for which the required response was given (for uniformity, thoroughness, and clarity) or ranking the responses to each component and summing the ranks (for size). The final scores were expressed as percentages of the maximum possible scores.
The analysis of the 4 features showed that investigators in large studies tend to perform more thorough analyses but are less uniform in the way they handle the primary studies (Web Figure 3) . The decrease in uniformity of methods with the increase in meta-analysis size was observed for study design, genotyping platforms, and quality control filters (P < 0.01) but not for adjustment for covariates (Figure 1 and Web Table 8 ). Unexpectedly, lower uniformity was not associated with greater assessment of heterogeneity and investigation of its possible causes (Web Table 8 ). The clarity of the reports was not dependent on any of the other 3 features.
Over time, meta-analyses got larger (P ¼ 0.01) and less uniform (P ¼ 0.02) but not significantly more thorough (P ¼ 0.25) or any clearer (P ¼ 0.44). Meta-analyses published in journals with an impact factor greater than 20 tended to be larger (P < 0.01) and more thorough (P < 0.01), but no more consistent (P ¼ 0.51) or more clearly reported (P ¼ 0.76). Consideration of heterogeneity was higher for journals with a high impact factor (Web Table 9 ).
There was considerable divergence in the ways in which SNPs were selected for replication and in the way that replication was judged. Meta-analyses with higher uniformity (P ¼ 0.02) and those that were less clearly reported (P ¼ 0.03) were more likely to use extra criteria over and above the discovery P value in selecting SNPs for replication. Larger meta-analyses were more likely to use combined evidence from discovery and replication (P ¼ 0.04) when deciding whether a SNP was a true hit.
DISCUSSION
Organizing the GWA meta-analysis
Use of individual data versus summary data. A practical question encountered when organizing a GWA meta-analysis is whether to ask for individual-level data or be satisfied with summary results from GWA studies. The latter approach, which was used by most meta-analyses, simplifies data collection and, depending on the form of the subjects' consent, may be the only option available for some primary studies. Use of summary results increases the willingness of investigators to join the GWA meta-analysis but requires returning to the primary investigators whenever more in-depth analyses are planned. This can be limiting, as illustrated by the much less frequent application of haplotype analysis in meta-analyses that relied on summary data.
Uniformity in methods used in primary studies. In the meta-analyses reviewed, primary studies often differed in study design. Pooling of family-based and population-based studies can introduce heterogeneity due to differences in population stratification and disease heterogeneity and to the different roles played by gene-gene and gene-environment interactions (24) . Mixing case-control studies and cohort studies may also lead to heterogeneity. Case-control studies frequently include prevalent cases with the potential for survival bias, whereby the genetic effect is underestimated if the variant increases the risk of disease-related mortality, and formulae to quantify this effect have recently been proposed (25) . Subgroup analyses should be used to investigate whether inclusion of different study designs introduces heterogeneity, yet this was performed in only 1 meta-analysis (26) .
The use of different genotyping platforms and different thresholds for genotyping quality control procedures should also be considered a potential source of heterogeneity. Primary studies often used different platforms, mainly from different manufacturers for which the overlap in SNPs tends to be low (27) , and used imputation to create a common set of SNPs and to increase power to detect associations (6, 28) . However, genotyping errors in individual studies, which vary across platforms, can be high (29) , as are batch effects (30) , and these can influence the imputation quality, particularly for low-frequency variants (31) . On the contrary, the frequently observed use of different imputation programs is unlikely to cause heterogeneity given the high agreement between MACH (12) and IMPUTE (32) , which were by far the most commonly used programs (33, 34) . For imputation, only 1 study used PLINK (35) , which is computationally less intensive and has shown worse performance (34) . Potentially more problematic are differences in the National Center for Biotechnology Information build, since corrections and changes in nomenclature across builds may lead to misalignment, with some studies being unable to contribute to the metaanalysis of specific SNPs. Similarly, differences in the HapMap reference data set used may introduce variability in imputation quality.
In most meta-analyses, the primary studies had adjusted the results for covariates, and one-quarter of the time adjustment varied across studies. Confounding by classical risk factors is not to be expected in genetic association studies (36) , but adjustment for nonconfounders should not introduce bias unless they include factors that are on the causal pathway to the disease (10) . Adjustment for different covariates across studies is potentially an important source of heterogeneity and should be avoided wherever possible.
Only in a minority of meta-analyses of population-based studies were identification and correction for population stratification and cryptic relatedness performed in all primary studies. Sometimes their assessment was purely based on study-specific genomic control lambda values, with correction for lambda considered sufficient and no more detailed investigation of the sources. In some studies, investigators also calculated the lambda values for the meta-analysis results and adjusted for a second time. A large lambda for pooled results is likely to be due to between-study heterogeneity, which should be investigated and addressed instead (10) .
Performing the GWA meta-analysis Choice of genetic model. All GWA meta-analyses used an additive genetic model. In general, this model performs well when the true underlying genetic model is uncertain (37), although simulation work has shown that it may perform poorly for variants with a recessive effect and a low minor allele frequency (38) , and it has been suggested that testing for both an additive and a recessive model in GWA meta-analysis may help to detect less common genetic variants (39) . While the use of an additive model only is reasonable at the genomewide level, the lack of further consideration of this issue in secondary analyses on top hits is surprising, given that misspecification of the genetic model can lead to biased results (40) . Meta-analyses performed on a large number of studies offer the opportunity to estimate the true underlying genetic model from the data (40, 41) , and such information could inform future prediction models and follow-up functional studies (42) .
Methods for pooling and investigation of heterogeneity. In the majority of meta-analyses, the pooling parameter was the effect size rather than the P value, and often studies performing a meta-analysis of P values as the primary analysis also pooled effect sizes. Meta-analysis of P values does not provide information on the magnitude of the genetic effect but can be useful when outcomes are measured in different ways across studies.
Data pooling was almost always based on a fixed-effects meta-analysis model, despite the fact that in about half of all meta-analyses there was no reported exploration of heterogeneity. Assessment of heterogeneity in secondary analyses of top hits should always be performed and its possible causes investigated. Whenever causes of heterogeneity can be identified-for example, variation of the genetic effect across populations-pooled estimates should be adjusted for them. More problematic are situations in which substantial heterogeneity remains unexplained, where the use of a random-effects model is preferable since it allows for some heterogeneity, but it does not solve the problem of how to interpret the differences in the genetic effects and their average estimate. In such cases, pooled estimates need to be interpreted as suggestive rather than conclusive, and further investigation is required to understand the causes of the observed heterogeneity (10) . Heterogeneity tests are unreliable when the meta-analysis includes few primary studies because of their low statistical power. This is why a significance threshold of 0.10 is often used in other contexts (43) , although clearly stricter thresholds are required if one is testing at a genome-wide level. Tests for heterogeneity do not themselves quantify the extent of the problem, and the magnitude of heterogeneity, measured by I 2 , was reported in one-quarter of the meta-analyses. I 2 is interpreted as the percentage of variability in study estimates that is explained by heterogeneity rather than sampling error (44) , and it has the advantage of not depending on the number of studies in a meta-analysis, but it depends on the precision of the studies. Therefore, between-study variance would provide a better measure of heterogeneity in meta-analyses including studies with large sample sizes, which is not uncommon in GWA metaanalyses (45) .
The scant consideration of heterogeneity in GWA metaanalyses was one of the major weaknesses of the reviewed meta-analyses. Heterogeneity is important when interest is in gene discovery, since theoretical work has shown that beyond a certain amount of heterogeneity, increasing the sample size does not help identify a signal (8) , and it becomes even more important when the aim moves towards gene characterization, where the identification of causes of heterogeneity may improve understanding of gene-disease associations (46) .
Replicating the GWA findings
Is replication necessary in a GWA meta-analysis? The majority of the meta-analyses used in silico replication based on other GWA studies. There is no consensus on whether grouping available GWA studies into a ''discovery phase'' and a ''replication phase'' is advantageous compared with pooling all samples into a single GWA metaanalysis. When the final decision about the presence of a true SNP association is to be based on the combined discovery and replication samples, as was most often the case, there is no advantage in combining only the top hits from the discovery in a 2-stage design when all SNPs have already been genotyped in stage 2. The 2-stage approach is advantageous only when the cost of de novo replication can be reduced. In contrast, other investigators based the final decision on the replication sample alone. This approach is slightly less powerful but offers greater protection against the effects of bias in the discovery (47) , and it gives effect sizes free from the winner's curse. The upward bias in the discovery sample due to the selection of top hits is often quite marked and, if uncorrected, will almost certainly cause heterogeneity between discovery and replication and bias the pooled effect size. Ideally, the effect size of a top hit from the discovery sample should be corrected for selection before combining it with the effect size from the replication sample (48), although this was not done in the meta-analyses reviewed.
Criteria for selection of SNPs for replication. In the reviewed meta-analyses, on average 21 SNPs were selected for replication and 4 were confirmed, although the criteria for declaring replication and for adjusting for multiple comparisons were often unclear. Criteria for the selection of SNPs for replication were mostly based solely on the strength of the statistical evidence from the discovery meta-analysis. Biologic knowledge or other previous evidence was considered in less than one-quarter of meta-analyses, but such evidence was not identified in a systematic way. This leaves the reader in doubt about whether a SNP was selected simply because the investigators happened to have specific knowledge about that gene, while perhaps another SNP with even higher support from previous evidence was omitted.
When power calculations for replication were performed, they were mostly post hoc calculations. Power calculations are most helpful in the design phase, when deciding on the balance between the size of the replication sample and the number of SNPs selected for replication. For this reason, post hoc power calculations are of limited value (49) , while a priori calculations of either the expected power to replicate given a certain sample size or the sample size required to achieve a certain power to replicate are crucially important in order to limit the possibility of false nonreplication (8) . Power calculations should be performed while accounting for the winner's curse, particularly when discovery metaanalyses have relatively small sample sizes (50) . The majority of the reviewed meta-analyses had good power to replicate the SNP with the largest effect, but nearly one-third of them had low power to replicate the SNP with the smallest effect. Moreover, power to replicate worsened substantially after accounting for a modest bias due to the winner's curse.
Writing the report
Findings from a meta-analysis are valid if results from the studies being pooled are valid. Readers can judge the validity of primary studies only if there is complete reporting of quality criteria, but full reporting of such indicators as genotype quality control filters and lambda values for all studies occurred in only half of the meta-analyses. Reporting was sometimes incomplete regarding basic information on metaanalysis methods, such as the weights used for pooling. There was little use of graphical methods to display study-specific results and heterogeneity, with only about one-quarter of meta-analyses showing forest plots. Forest plots, which have been routinely used in meta-analysis for 30 years (51), highlight the issue of heterogeneity by providing immediate information on individual study findings and variability in individual estimates.
The need for further methodological research
This review suggests that research groups are making a large number of rather ad hoc decisions when meta-analyzing their data and that they lack research evidence to guide their choices. This has resulted in a great deal of variation in approaches. For instance, the choice to meta-analyze studies that have used similar methods may increase power to detect associations by reducing heterogeneity, but it may reduce power by excluding some studies. Finding the best tradeoff is difficult in the absence of evidence on which to base the decision. A further example is the use of HWE tests as a quality control criterion for excluding SNPs, which is important for meta-analyses performed on genotyped data and less so for meta-analyses on imputed data where genotyping errors can be partially corrected for. The review shows that most groups employ this filter, but they do so at different P values, sometimes testing unaffected persons and sometimes testing everyone. Simulations or empirical investigations using data from one of the large consortia could answer questions such as, ''If the genotyping error goes above 3%, what chance do we have of detecting it by HWE testing at P ¼ 10 À4 ?'' or ''If primary studies use a range of P values in their HWE filter, will it introduce noticeable heterogeneity in the effect size?'' Similarly important would be to know how much heterogeneity is introduced by the use of different genotyping platforms or different methods of imputation. Answers to these types of practical questions would be invaluable in standardizing the approach to GWA meta-analyses and improving their overall quality.
Conclusions
A great variety of methods are being used for GWA metaanalysis, but the rationale on which the choice is based is often unclear. Although guidelines for the conduct of GWA meta-analysis would be of great value, more methodological work is required on some of the issues highlighted by this review before clear guidance can be offered as to optimal methods or tradeoffs between alternative methods. However, there is a clear need for guidelines for reporting. Previous experience has shown the importance of surveys documenting current practice in development of guidelines (52) , and this review provides such an empirical basis by showing aspects of reporting of GWA meta-analysis that are receiving insufficient attention.
